Autoantibodies to kininogen-phosphatidylethanolamine complexes augment thrombin-induced platelet aggregation
1Tokai University School of Medicine, Kanagawa, Japan.
Thrombosis Research
|October 15, 1996
Summary
Certain anti-phosphatidylethanolamine (aPE) antibodies target kininogens, proteins that inhibit platelet aggregation. These antibodies may promote thrombosis by disrupting kininogen
Area of Science:
- Immunology
- Hematology
- Thrombosis Research
Background:
- Autoantibodies to phosphatidylethanolamine (PE) are linked to thrombotic diseases.
- Some anti-PE antibodies (aPE) target PE-binding plasma proteins: high molecular weight kininogen (HK) and low molecular weight kininogen (LK).
- Kininogens inhibit thrombin-induced platelet aggregation but not aggregation induced by other agonists.
Purpose of the Study:
- To investigate if aPE can recognize platelet-bound kininogens and interfere with their antithrombotic function.
- To determine if kininogen-dependent aPE can promote thrombosis by disrupting kininogen's inhibitory effects on platelets.
Main Methods:
- Experiments using purified kininogens and PE in vitro.
- Assays measuring platelet aggregation induced by thrombin or ADP in the presence of kininogen-dependent and kininogen-independent IgG aPE.
Main Results:
- Kininogens bind to PE in vitro, suggesting a potential mechanism for platelet binding.
- Kininogen-dependent IgG aPE significantly increased thrombin-induced platelet aggregation in vitro.
- Kininogen-independent IgG aPE, recognizing PE directly, did not enhance thrombin-induced platelet aggregation.
Conclusions:
- Kininogen-dependent aPE may contribute to thrombosis in vivo.
- This prothrombotic effect is likely due to the disruption of kininogen's natural antithrombotic activity.
- Further research is needed to elucidate the precise mechanisms of kininogen-platelet interactions and aPE involvement in thrombosis.
Related Concept Videos
01:17Intracellular Signaling Affects Focal Adhesions
Integrins act both as extracellular input receivers and as intracellular processing activators. As their name suggests, integrins are entirely integrated into the membrane structure. Their hydrophobic membrane-spanning regions interact with the phospholipid bilayer's hydrophobic region. These membrane receptors provide extracellular attachment sites for effectors like hormones and growth factors. They activate intracellular response cascades when their effectors are bound and active.
Some...
Some...
01:30Anticoagulant Drugs: Low-Molecular-Weight Heparins
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
01:22Formation of the Platelet Plug
The platelet phase, the second stage of hemostasis, commences around 15-20 seconds after an injury. It follows and overlaps with the vascular phase, during which blood vessels constrict to minimize blood loss.
As the injured blood vessel contracts, endothelial cells undergo contraction, revealing collagen fibers in the basement membrane and underlying connective tissue. Furthermore, the plasma membrane of endothelial cells becomes adhesive, preparing the site for platelet adhesion. Platelets...
As the injured blood vessel contracts, endothelial cells undergo contraction, revealing collagen fibers in the basement membrane and underlying connective tissue. Furthermore, the plasma membrane of endothelial cells becomes adhesive, preparing the site for platelet adhesion. Platelets...
01:16Clot Retraction and Fibrinolysis
After a fibrin clot is formed, the next step is clot retraction, a vital process facilitated by platelet contractile proteins, such as actin and myosin. These proteins pull the fibrin strands closer together and condense the clot. This action reduces the size of the clot, creating a smaller, denser structure that effectively seals off the damaged vessel. Clot retraction consolidates the clot and helps with wound healing by bringing the edges of the damaged blood vessel closer together.
01:23Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...